Ferro announced that it has successfully concluded negotiations on an amendment to its credit agreement. The amendment provides the Company with additional flexibility under the financial performance covenants contained in the agreement. The size of the credit facility remains at $300 million for the revolving credit facility and $292.5 million in term loans. Interest rates on the Company’s borrowings and other terms of the facility were amended.

Songwon has got extensive warehousing facilities and a packaging line at one of the most important distribution points in Europe.

Working together with ADPO (Antwerp Distribution & Products Operations), an expert with more than 20 years experience in integrated distribution systems for the chemical industry, Songwon has secured a dedicated packaging line and inventory space, not only for solid products, but also liquids materials which is one of the areas of expertise that ADPO provides.

Gilead Sciences and CV Therapeutics announced the signing of a definitive agreement pursuant to which Gilead will acquire CV Therapeutics for $20.00 per share in cash through a tender offer and second step merger. CV Therapeutics’ Board of Directors has unanimously approved the transaction and has agreed to recommend to its stockholders that they tender their shares pursuant to the tender offer. CV Therapeutics will become a wholly-owned subsidiary of Gilead. The transaction is valued at approximately $1.4 billion.

CV Therapeutics focuses on the development of small molecule drugs for the treatment of cardiovascular diseases. In 2008, its two marketed products, Ranexa® (ranolazine extended-release tablets), indicated for the treatment of chronic angina, and Lexiscan® (regadenoson) injection for use as a pharmacologic stress agent in radionuclide myocardial perfusion imaging in patients unable to undergo adequate exercise stress, contributed to total revenues of $154.5 million. CV Therapeutics’ pipeline includes multiple product candidates currently being evaluated for the treatment of atrial fibrillation, pulmonary diseases and diabetes.

The tender offer is expected to close during the second quarter of 2009. Following completion of the tender offer, Gilead will acquire all remaining shares of CV Therapeutics through a second step merger at a price of $20.00 per share. Merrill Lynch & Co. is acting as the exclusive financial advisor to Gilead in the transaction. Barclays Capital and Goldman, Sachs & Co. are acting as financial advisors to CV Therapeutics. Cooley Godward Kronish LLP is serving as legal counsel to Gilead and Latham & Watkins LLP is serving as legal counsel to CV Therapeutics.

Aker Solutions has been awarded another contract for the delivery of a deepwater drilling riser system to Daewoo Shipbuilding & Marine Engineering (DSME). Contract value is approximately USD 36.5 million.

This is the fifth deepwater drilling riser system contract DSME has awarded Aker Solutions since last year, taking the total drilling riser orders from the Korean yard up to NOK 1 billion.

This latest contract is for the delivery of a complete deepwater marine drilling riser system with buoyancy package and associated equipment. The new drilling riser is based on an identical design for the ongoing projects at DSME.

The marine drilling riser system will be manufactured and delivered out of Aker Solutions’ manufacturing centre in Malaysia.

Delivery of the drilling riser system is scheduled for 2011. Contract party is Aker Solutions Malaysia Sdn. Bhd.

We will take part in FIC 2009 in China and Welcome to !

No.88,Caobao Rd., Shanghai Everbright Convention & Exhibition Center West Hall (2F)

our booth :2A088

2009-1-20